Aura Biosciences Inc: Strong Buy Rating Backed by Promising Clinical Progress and Strategic Oncology Expansion
H.C. Wainwright's Andres Y. Maldonado reiterated a Buy rating for Aura Biosciences Inc, with a $22 price target. The rating is supported by promising clinical progress, including the Phase 3 CoMpass trial in choroidal melanoma, and strategic expansion into oncology areas like bladder cancer. The company has received Orphan Drug and Fast Track designations for its bel-sar treatment, indicating potential effectiveness and importance. These factors suggest strong potential for value inflection.
In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Aura Biosciences Inc, with a price target of $22.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andres Y. Maldonado has given his Buy rating due to a combination of factors related to Aura Biosciences Inc’s ongoing clinical programs and potential in oncology. The company’s Phase 3 CoMpass trial in early choroidal melanoma is progressing well, with a significant number of clinical sites activated and patients pre-screened. The trial is under a Special Protocol Assessment with the FDA, indicating strong regulatory alignment, and is expected to provide topline data by the fourth quarter of 2027.
Furthermore, Aura Biosciences Inc has received Orphan Drug and Fast Track designations for its bel-sar treatment, which supports its potential effectiveness and importance. The company’s strategic expansion into other oncology areas, such as non-muscle invasive bladder cancer, and the promising early data showing bel-sar’s ability to induce immune responses, further bolster confidence in its platform. These developments suggest a strong potential for value inflection, justifying the Buy rating and a price target of $22.
